The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Antibody–Drug Conjugates for Cancer Therapy
Open accessAbstract
Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity to normal tissue, achieving wider therapeutic windows and enhanced pharmacokinetic/pharmacodynamic properties. To date, nine ADCs have been approved by the FDA and more than 80 ADCs are under clinical development worldwide. In this paper, we provide an overview of the biology and chemistry of each component of ADC design. We briefly discuss the clinical experience with approved ADCs and the various pathways involved in ADC resistance. We conclude with perspectives about the future development of the next generations of ADCs, including the role of molecular imaging in drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–210 of 210
Johnson, M. L., El-Khoueiry, A. B., Hafez, N., Lakhani, N. J., Mamdani, H. M., Rodon, J. A., Sanborn, R. E., Ho, T., Li, R., Waldes, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.3502 · Cited by 18
Moore, K. N., Ponte, J., LoRusso, P. M., Birrer, M. J., Bauer, T. M., Borghaei, H., O’Malley, D. M., Ruiz-Soto, R., Lutz, R., & Malik, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.5571 · Cited by 16
Wang, R., Li, L., Duan, A., Li, Y., Liu, X., Miao, Q., Gong, J., & Zhen, Y. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.002 · Cited by 16
Masuda, N., Yonemori, K., Takahashi, S., Kogawa, T., Nakayama, T., Iwase, H., Takahashi, M., Toyama, T., Saeki, T., Saji, S., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.sabcs18-pd1-03 · Cited by 16
García-Corbacho, J., Spira, A. I., Boni, V., Feliú, J., Middleton, M. R., Burris, H. A., Weaver, A. M., Will, M., Harding, J. J., Meric‐Bernstam, F., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx367.055 · Cited by 13
Lopez, D. M., Barve, M. A., Wang, J., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-19-b005 · Cited by 13
Mantaj, J., Jackson, P. J., Karu, K., Rahman, K. M., & Thurston, D. E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152303 · Cited by 12
Radford, J. A., Kahl, B. S., Hamadani, M., Carlo‐Stella, C., Caimi, P. F., Ardeshna, K. M., Feingold, J. M., He, S. X., Reid, E. G., Solh, M., et al. (2018) · Blood · doi:10.1182/blood-2018-99-116081 · Cited by 9
Johnson, D. A., & LAGUZZA, B. C. (1988) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(88)90249-8 · Cited by 8
Scribner, J. A., Brown, J. G., Sharma, S., Li, H., Chiechi, M., Li, P., Son, T., Costa, A. D., Chen, Y., Chen, F., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-820 · Cited by 5
Cited by
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., Hou, P., Cui, Q., Xu, Z., Wang, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01704-3 · Cited by 285
Zhu, Y., Liu, K., Wang, K., & Zhu, H. (2023) · Cancer · doi:10.1002/cncr.34507 · Cited by 192
Targeting CLDN18.2 in cancers of the gastrointestinal tract: new drugs and new indications
Chen, J., Xu, Z., Hu, C., Zhang, S., Zi, M., Yuan, L., & Cheng, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1132319 · Cited by 78
Metadata
- Authors
- Hafeez, U., Parakh, S., Gan, H. K., & Scott, A. M.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-10-16
- Volume
- 25
- Issue
- 20
- Pages
- 4764
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W3093149563
- Cited by
- 395
- References
- 210
- FWCI
- 21.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.